Published on November 30, 2012 at 1:54 AM
Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier: NCT01417000). Enrollment was completed eight months ahead of schedule.
"We believe the rate of enrollment demonstrates significant interest in this vaccine treatment from our clinical investigators and their patients and reflects the high-quality work and dedication of our clinical trial sites," said Dr. Dirk Brockstedt, Senior Vice President of Research and Development at Aduro.
The vaccine regimen has been administered in an outpatient setting and has been well-tolerated thus far with no serious or unexpected adverse events related to the study vaccines. A formal interim analysis of the safety and efficacy of the randomized, controlled trial is expected in the first quarter of next year.
"Metastatic pancreatic cancer is a devastating disease," said Stephen Isaacs, Chairman and Chief Executive Officer of Aduro. "We are optimistic that the results of this trial will reveal a promising new therapeutic option that can extend life and increase quality of life."
Source: Aduro BioTech, Inc.